<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472212</url>
  </required_header>
  <id_info>
    <org_study_id>2001H0401</org_study_id>
    <nct_id>NCT00472212</nct_id>
  </id_info>
  <brief_title>Correction of Farsightedness in Children Study</brief_title>
  <acronym>CHICS</acronym>
  <official_title>Correction of Hyperopia in Children Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Academy of Optometry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Transitions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio Lions Eye Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>College of Optometrists in Vision Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SUNY Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Correction of Hyperopia In Children Study (CHICS) is a placebo-controlled, randomized,
      masked investigation of the effect of spectacle correction for moderate amounts of hyperopia
      on visual function, attention, and reading skills in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperopia (farsightedness) has been reported to be associated with reduced visual perceptual
      and reading abilities. However, there is controversy regarding whether or not to prescribe
      for low to moderate amounts of hyperopia. The Correction of Hyperopia In Children Study
      (CHICS) is a placebo-controlled, randomized, masked investigation of the effect of spectacle
      correction for moderate amounts of hyperopia on visual function, attention, and reading
      skills in children.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Kaufman Test of Educational Achievement (K-TEA) reading comprehension score as measured after 6 weeks of assigned treatment (hyperopic or control correction)</measure>
    <time_frame>6 week outcome exam</time_frame>
    <description>Individually administered battery that provides in-depth assessment of key academic skills</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Assessment System (CAS) Attention scores as measured after 6 weeks of assigned treatment (hyperopic or control correction)</measure>
    <time_frame>6 week outcome exam</time_frame>
    <description>Individually administered battery designed to measure cognitive processing abilities. CAS is based on PASS (Planning, Attention, Simultaneous, and Successive), a well-researched cognitive/neuropsychological theory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in accommodative response after 6 weeks of assigned treatment (hyperopic or control correction)</measure>
    <time_frame>6 week outcome exam</time_frame>
    <description>Accommodative response by monocular estimation method (MEM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hyperopia</condition>
  <condition>Farsightedness</condition>
  <arm_group>
    <arm_group_label>Spectacles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spectacles with hyperopic lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Spectacles with placebo lenses</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectacles</intervention_name>
    <description>Hyperopic spectacle lenses</description>
    <arm_group_label>Spectacles</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Plano (no power, control) spectacle lenses</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6-11 years;

          -  At least +1.00D Hyperopia (farsightedness);

          -  &lt; +4.00D Hyperopia;

          -  &lt; 1.00D Astigmatism;

          -  &lt; 1.00D Anisometropia (difference between the two eyes);

          -  Willing to be randomized;

          -  Best corrected visual acuity of 20/25 or better in each eye;

          -  Willing to wear eyeglasses full-time;

          -  Willing to return for follow-up visits

        Exclusion Criteria:

          -  Previous wear of glasses or contacts for farsightedness/hyperopia;

          -  Eye disease that affects visual function;

          -  Amblyopia (lazy eye);

          -  Strabismus (eye turn);

          -  History of strabismus surgery;

          -  Chronic use of any of the following medications:

               -  Antianxiety agents (Librium, Valium)

               -  Antiarrythmic agents (Cifenline, Cibenzoline)

               -  Anticholinergics (Motion sickness patch - scopolamine)

               -  Bladder spasmolytic (Propiverine)

               -  Chloroquine

               -  Phenothiazines (Compazine, Mellaril, Thorazine)

               -  Tricyclic antidepressants (Elavil, Nortriptyline, Tofranil)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjean Kulp, OD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Illinois College of Optometry/Illinois Eye Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY College of Optometry/University Optometric Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern College of Optometry</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 9, 2007</study_first_submitted>
  <study_first_submitted_qc>May 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2007</study_first_posted>
  <last_update_submitted>August 17, 2018</last_update_submitted>
  <last_update_submitted_qc>August 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Marjean Kulp</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

